I am pleased to share with you our 2024 Annual Report, released at our recent Annual General Meeting on 21 May, 2025.
Please click here to access the report.
After substantial membership growth over the previous year our membership remained stable in 2024, maintaining strong representation across all major Australian states and New Zealand, importantly with more than 30% of our Members situated in rural or regional locations.
A total of 274 clinical trial submissions were supported by CTA across 2024, a 7% increase on the previous year. Amendments grew 21%, patients recruited to CTA supported trials grew 11% to 1,810 patients, and total clinical trial funding administered on behalf of our service Members grew 13% to a new record of over $59M.
Other highlights across 2024 included the release of our ESG framework, receiving endorsement of our first Reconciliation Action Plan from Reconciliation Australia, transitioning our Tumour Group information to a web accessible form, convening a national Phase 1 strategy meeting, continuing to support the Developmental Therapeutics Update dinner series across its second year, and hosting our largest Research Managers’ meeting ever.
Cancer Trials Australia remains well positioned to continue to support growing clinical trial activity across our membership, helping to secure earlier access to novel therapies for Australian cancer patients.
I thank all CTA staff, as well as our network Member personnel, for all the hard work they undertake that is essential to enable the CTA network to flourish.
Kurt Lackovic PhD MBA GAICD
Chief Executive Officer